Redeye provides its initial take on Surgical Science’s Q2 2025 report, which aligned with its profit warning and underperformed our original projections across the board. We expect to lower our estimates and valuation, though Surgical Science features high q/q volatility and should be able to post better figures in coming quarters.
LÄS MER
